RA
AKCA

Royce & Associates’s Akcea Therapeutics Inc AKCA Stock Holding History

Royce & Associates’s Portfolio AKCA Stock Details AKCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-2,152
Closed -$29K – 1219
2020
Q2 		$29K Buy
2,152
+10
+0.5% +$154 ﹤0.01% 1100
2020
Q1 		$31K Buy
+2,142
New +$35.2K ﹤0.01% 1063

Other funds holding AKCA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $15.7B AUM 36.4% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Royce & Associates's AKCA Position: Q3 2020 in Review

Royce & Associates sold out of Akcea Therapeutics Inc (AKCA) in Q3 2020, closing a stake of 2,152 shares — an estimated $29K sold.

Royce & Associates first reported a position in AKCA in Q1 2020 and held it in 2 quarters. The position peaked at $31K in Q1 2020. 98 funds tracked by Wall St. Rank hold AKCA as of Q3 2020.

  • Royce & Associates reported no remaining Akcea Therapeutics Inc position as of Q3 2020 after selling out during the quarter.
  • Royce & Associates sold 2,152 Akcea Therapeutics Inc shares in Q3 2020, an estimated $29K.
  • Royce & Associates first reported a position in Akcea Therapeutics Inc in Q1 2020 and held it in 2 quarters.
  • Royce & Associates's Akcea Therapeutics Inc position peaked at $31K in Q1 2020.
  • 98 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q3 2020.

Based on Royce & Associates's 13F filing for Q3 2020, filed 12 Nov 2020.